Core–shell type lipid–polymer hybrid nanoparticles (CSLPHNPs) have emerged as a
multifunctional drug delivery platform. The delivery system combines mechanical …

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in
China. This study aimed to develop a hyaluronic acid (HA) decorated, pH sensitive lipid …

Non-small cell lung cancer (NSCLC) patients with sensitizing mutations in the exons 18–21
of the epithelial growth factor receptor (EGFR) gene show increased kinase activity of EGFR …

In this study, a core-shell type polypeptide-based lipid nanocapsule was developed to
enhance anticancer efficacy of erlotinib in non-small cell lung cancers. Mean particle size of …

Abstract Background and objectives Erlotinib HCl is approved for the treatment of metastatic
non-small cell lung cancer. Owing to its poor aqueous solubility and presystemic …

Erlotinib (ELT) as a small molecule with poor solubility, poor bioavailability, and instability in
gastrointestinal environment, has been considered as a therapeutic agent for Non-Small …

This study was aimed at developing a nanoparticle strategy to overcome acquired
resistance against erlotinib in non-small cell lung cancer (NSCLC). To load erlotinib on …

Special targeted therapy like endothelial growth factor receptor (EGFR) targeted therapy is
available for the treatment of advanced non-small cell lung cancer (NSCLC). Biodegradable …

Lipid polymer hybrid nanoparticles (LPHNPs) have been merged as potential nanocarriers
for treatment of cancer. In the present study, LPHNPs loaded with Sorafenib (SFN) were …

Background Aim of this study was to prepare the hyaluronic acid and human serum albumin
modified erlotinib nanoparticles (ERT-HSA-HA NPs) delivery system by a precipitation …